MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:28Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Thiazide diuretics]]
			[[Category:Antihypertensives]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #16

2026-05-23T03:29:42Z

parser-claude batch MedTemplate pre-fill, Top 300 #16

New page

{{MedTemplate
| generic = Hydrochlorothiazide
| brand = Microzide; mostly prescribed generically
| structure =
| classes = [[:Category:Thiazide_diuretics|Thiazide diuretic]], [[:Category:Antihypertensives|Antihypertensive]]
| uses = <vote slug="hypertension-use">Hypertension</vote>, <vote slug="edema-use">Edema (heart failure, hepatic, renal)</vote>, <vote slug="nephrogenic-di-use">Nephrogenic diabetes insipidus</vote>, <vote slug="calcium-stone-prevention-use">Calcium-stone prevention</vote>
| starting_dose = 12.5-25 mg PO once daily
| preparations = 12.5 mg capsules; 12.5, 25, 50 mg tablets
| fda_max = 50 mg/d (hypertension); up to 200 mg/d (edema)
| pill_id =
| routes = Oral
| onset = Diuresis at 2 hours; antihypertensive effect within days, max at 3-4 weeks
| duration = 6-12 hours
| halflife = 6-15 hours<ref name="microzide-label">FDA Prescribing Information, Microzide (hydrochlorothiazide), Watson, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/040735s011lbl.pdf</ref>
| bioavailability = 65-75% (oral)<ref name="microzide-label" />
| pregnancy = Avoided where possible; can reduce placental perfusion and produce neonatal thrombocytopenia, jaundice, electrolyte disturbance. Labetalol or nifedipine preferred for chronic hypertension in pregnancy.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="hctz-mech-claim">Hydrochlorothiazide inhibits the Na+/Cl- cotransporter (NCC) in the apical membrane of distal convoluted tubule cells, blocking sodium reabsorption and producing modest natriuresis with longer-term peripheral vasodilation that accounts for most of its antihypertensive effect.</vote> Decreases urinary calcium (used in stone prevention); raises serum uric acid, glucose, and lipids modestly; non-anion-gap hypokalemic metabolic alkalosis is the characteristic electrolyte pattern<ref name="microzide-label" />.
}}

== References ==
<references />

Hydrochlorothiazide - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #16